Improvement effect of recombinant human erythropoietin on cognition disorders in acute brain infarction patients

doi:10.3877/cma.j.issn.1674-6880.2017.02.004

Abstract

Abstract:

Objective

To study the improvement effect of recombinant human erythropoietin (rHu-EPO) on cognition disorders in acute brain infarction patients.

Methods

Acute brain infarction patients with cognition disorders were randomly divided into the control group (16 cases) and rHu-EPO group (18 cases), and two cases in each group were initiatively dropped out during therapy. Patients in the control group received conventional treatment, and patients in the rHu-EPO group were given subcutaneous injection of 30 IU/kg rHu-EPO 3 times per week, and lasted for 4 weeks additionally. Montreal cognitive assessment scales (MOCA) were used to evaluate cognitive function, neural function defect were scaled according to the national institutes of health neurological deficit score (NIHSS) and infarction sizes were determined by magnetic resonance imaging before and after therapy.

Results

Compared with before therapy, the MOCA score (t = 1.684, P = 0.035; t = 3.622, P = 0.011), language function scores (t = 2.258, P = 0.025; t = 3.472, P = 0.019) and delayed memory function scores (t = 2.665, P = 0.018; t = 4.826, P = 0.026) in the control group and rHu-EPO group all increased markedly, and the MOCA score [(20.21 ± 2.63) vs. (16.99 ± 2.28); t = 4.183, P = 0.011], language function scores [(2.76 ± 0.83) vs. (1.66 ± 0.71); t = 4.865, P = 0.008] and delayed memory function scores [(4.66 ± 1.38) vs. (3.12 ± 1.02); t = 2.643, P = 0.025] in the rHu-EPO group were much higher than those in the control group. After therapy, the NIHSS in the control group and rHu-EPO group were also lower than those before therapy (t = 3.506, 8.126, P = 0.018, 0.002), and in the rHu-EPO group reduced obviously as compared with that in the control group (t = 2.508, P = 0.026). Meanwhile, the infarction sizes after therapy only in the rHu-EPO group decreased as compared with before therapy [(12.8 ± 3.5) cm³ vs. (8.2 ± 2.3) cm³; t = 6.204, P = 0.001], and in the rHu-EPO group were much smaller than those in the control group (t = 3.268, P = 0.022).

Conclusion

Based on conventional therapy, rHu-EPO may effectively improve cognition disorders in acute brain infarction patients, especially language and delayed memory function.

Key words: Brain infarction, Cognition disorders, Recombinant human erythropoietin

Daihua Yu, Wei Li, Qian Yang, Xude Sun, Changjun Gao, Wei Chai. Improvement effect of recombinant human erythropoietin on cognition disorders in acute brain infarction patients[J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2017, 10(02): 87-91.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwzzyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6880.2017.02.004

https://zhwzzyxzz.cma-cmc.com.cn/EN/Y2017/V10/I02/87

Figures/Tables 2

References 20

1	吴锦波，吴平生，张宏斌，等. 促红细胞生成素对大鼠心肌缺血再灌注损伤的保护性作用[J]. 医学争鸣，2009，30(19):1894-1897.
2	刘锋，龙慧，梁江红. 局灶性脑缺血再灌注损伤模型大鼠与促红细胞生成素的神经保护作用[J]. 中国组织工程研究，2010，14(20):3718-3721.
3	Vinberg M, Miskowiak K, Hoejman P, et al. The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study[J]. PLoS One, 2015, 10 (5): e0127629.
4	Tojo Y, Sekine H, Hirano I, et al. Hypoxia signaling cascade for erythropoietin production in hepatocytes[J]. Mol Cell Biol, 2015, 35 (15): 2658-2672.
5	Torres J, Ishida K. Neuroprotection after major cardiovascular surgery[J]. Curr Treat Options Neurol, 2015, 17 (7): 357.
6	Larpthaveesarp A, Ferriero DM, Gonzalez FF. Growth factors for the treatment of ischemic brain injury (growth factor reatment) [J]. Brain Sci, 2015, 5 (2): 165-177.
7	祝慧凤，徐晓玉，万东，等. 促红细胞生成素促脑血管新生机制研究进展[J]. 中国药理学通报，2011，27(4):451-454.
8	Wang W, Li D, Li Q, et al. Erythropoietin promotes peripheral nerve regeneration in rats by upregulating expression of insulin-like growth factor-1[J]. Arch Med Sci, 2015, 11 (2): 433-437.
9	Pullicino P, Nelson RF, Kendall BE, et al. Small deep infarcts diagnosed on computed tomography[J]. Nearology, 1980, 30 (10): 1090-1096.
10	Vila JF, Balcarce PE, Abiusi GR, et al. Improvement in motor and cognitive impairment after hyperbaric oxygen therapy in a selected group of patients with cerebralvascular disease: a prospective sigle-blind controlled trial[J]. Undersea Hyperb Med, 2005, 32 (5): 341-349.
11	Lu J, Jiang L, Zhu H, et al. Hypoxia-inducible factor-1α and erythropoietin expression in the hippocampus of neonatal rats following hypoxia-ischemia[J]. J Nanosci Nanotechnol, 2014, 14 (8): 5614-5619.
12	Grote Beverborg N, Verweij N, Klip IT, et al. Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates[J]. PLoS One, 2015, 10 (4): e0125215.
13	于代华，蒋玮，彭细娟，等. 促红细胞生成素预处理对大鼠脑缺血再灌注损伤的影响[J/CD]. 中华危重症医学杂志（电子版），2013，12(6):339-343.
14	Jeong JH, Kang SH, Kim JH, et al. Protective effects of poly (lactic-co-glycolic acid) nanoparticles loaded with erythropoietin stabilized by sodium cholate against glutamate-induced neurotoxicity[J]. J Nanosci Nanotechnol, 2014, 14 (11): 8365-8371.
15	Xiong Y, Mahmood A, Meng Y, et a1. D Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose [J]. J Neurosurg, 2010, 113 (3): 598-608.
16	Xin B, Liu CL, Yang H, et al. Prolonged Fasting Improves Endothelial Progenitor Cell-Mediated Ischemic Angiogenesis in Mice[J]. Cell Physiol Biochem, 2016, 40 (3-4): 693-706.
17	Miller JL, Church TJ, Leonoudakis D, et al. Discovery and characterization of nonpeptidyl agonists of the tissue-protective erythropoietin receptor[J]. Mol Pharmacol, 2015, 88 (2): 357-367.
18	Giri P, Ebert S, Braumann UD, et al. Skin regeneration in deep second-degree scald injuries either by infusion pumping or topical application of recombinant human erythropoietin gel[J]. Drug Des Devel Ther, 2015 (9): 2565-2579.
19	程卫，李钟声. 促红细胞生成素治疗肾性贫血的进展[J]. 透析与人工器官，2008，19(3):19-22.
20	张明，高鑫，谷红霞，等. 大剂量促红细胞生成素治疗肾性贫血[J]. 实用医药杂志，2009，26(5):1-2.

组别	例数	性别（例，男/女）	年龄（岁， ± s）	文化程度
组别	例数	性别（例，男/女）	年龄（岁， ± s）	文盲	小学	中学以上
对照组	14	6/8	58 ± 16	7.1%	50%	42.8%
治疗组	16	6/10	62 ± 18	0	56%	43.8%
t/χ²值	?	0.285	0.324	?	0.861	?
P值	?	0.786	0.262	?	0.187	?
组别	例数	职业构成			并发疾病
组别	例数	体力劳动者	脑力劳动者	生理力劳动者	高血压	高血糖	高血脂
对照组	14	78.6%	14.3%	7.1%	28.6%	57.1%	71.4%
治疗组	16	62.5%	25%	12.5%	28.6%	43.8%	75%
t/χ²值	?	0.946			0.969
P值	?	0.105			0.062

组别	例数	性别（例，男/女）	年龄（岁， ± s）	文化程度
组别	例数	性别（例，男/女）	年龄（岁， ± s）	文盲	小学	中学以上
对照组	14	6/8	58 ± 16	7.1%	50%	42.8%
治疗组	16	6/10	62 ± 18	0	56%	43.8%
t/χ²值	?	0.285	0.324	?	0.861	?
P值	?	0.786	0.262	?	0.187	?
组别	例数	职业构成			并发疾病
组别	例数	体力劳动者	脑力劳动者	生理力劳动者	高血压	高血糖	高血脂
对照组	14	78.6%	14.3%	7.1%	28.6%	57.1%	71.4%
治疗组	16	62.5%	25%	12.5%	28.6%	43.8%	75%
t/χ²值	?	0.946			0.969
P值	?	0.105			0.062

组别		例数	MOCA总分（30）	视空间执行（5）	命名（3）	注意（6）
对照组		?	?	?	?	?
?	治疗前	14	14.75 ± 3.26	2.56 ± 0.48	1.25 ± 0.52	2.96 ± 0.23
?	治疗4周后	14	16.99 ± 2.28^a	3.39 ± 0.52	1.31 ± 0.66	3.13 ± 0.35
rHu-EPO治疗组		?	?	?	?	?
?	治疗前	16	15.08 ± 2.75	2.49 ± 0.44	1.29 ± 0.45	2.86 ± 0.32
?	治疗4周后	16	20.21 ± 2.63^ab	3.53 ± 0.59	1.35 ± 0.57	3.25 ± 0.42
t值		?	4.183	1.253	0.547	0.694
P值		?	0.011	0.196	0.208	0.331
组别		例数	语言（3）	抽象（2）	延迟回忆（5）	定向（6）
对照组		?	?	?	?	?
?	治疗前	14	1.25 ± 0.64	0.54 ± 0.26	2.68 ± 0.86	3.51 ± 1.26
?	治疗4周后	14	1.66 ± 0.71^a	0.73 ± 0.18	3.12 ± 1.02^a	3.65 ± 1.33
rHu-EPO治疗组		?	?	?	?	?
?	治疗前	16	1.29 ± 0.58	0.62 ± 0.25	2.85 ± 0.95	3.68 ± 1.08
?	治疗4周后	16	2.76 ± 0.83^ab	0.84 ± 0.22	4.66 ± 1.38^ab	3.82 ± 1.15
t值		?	4.865	1.106	2.643	0.876
P值		?	0.008	0.335	0.025	0.084

组别		例数	MOCA总分（30）	视空间执行（5）	命名（3）	注意（6）
对照组		?	?	?	?	?
?	治疗前	14	14.75 ± 3.26	2.56 ± 0.48	1.25 ± 0.52	2.96 ± 0.23
?	治疗4周后	14	16.99 ± 2.28^a	3.39 ± 0.52	1.31 ± 0.66	3.13 ± 0.35
rHu-EPO治疗组		?	?	?	?	?
?	治疗前	16	15.08 ± 2.75	2.49 ± 0.44	1.29 ± 0.45	2.86 ± 0.32
?	治疗4周后	16	20.21 ± 2.63^ab	3.53 ± 0.59	1.35 ± 0.57	3.25 ± 0.42
t值		?	4.183	1.253	0.547	0.694
P值		?	0.011	0.196	0.208	0.331
组别		例数	语言（3）	抽象（2）	延迟回忆（5）	定向（6）
对照组		?	?	?	?	?
?	治疗前	14	1.25 ± 0.64	0.54 ± 0.26	2.68 ± 0.86	3.51 ± 1.26
?	治疗4周后	14	1.66 ± 0.71^a	0.73 ± 0.18	3.12 ± 1.02^a	3.65 ± 1.33
rHu-EPO治疗组		?	?	?	?	?
?	治疗前	16	1.29 ± 0.58	0.62 ± 0.25	2.85 ± 0.95	3.68 ± 1.08
?	治疗4周后	16	2.76 ± 0.83^ab	0.84 ± 0.22	4.66 ± 1.38^ab	3.82 ± 1.15
t值		?	4.865	1.106	2.643	0.876
P值		?	0.008	0.335	0.025	0.084

[1]	Jialin Han, Pinjing Hui, Yanhong Yan, Chunhong Hu, Qi Fang. Correlation between cerebral hemodynamic parameters and cerebral infarction volume in patients with chronic middle cerebral artery occlusion [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2019, 16(08): 602-608.
[2]	Wulong Wu, Zezhou Song, Yanming Zhang, Yanfei Fu, Yu Geng. The prediction of recurrent cerebral infarction by the neovascularization grade of carotid plaque using contrast enhanced ultrasonography: a Logistic regression model analysis [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2018, 15(01): 43-47.
[3]	Xiuling Wang, Minyu Zhang, Guichun Ding, Hongbin Wang, Jianhua Wang. Quantitative evaluation of carotid plaque vulnerability by using GSM based on three dimensional ultrasound [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2017, 14(01): 23-28.
[4]	Zhan Liu, Yuntao Li, Shihong Li, Feiwu Long, Hailiang Ren, Jianhui Gu. Correlation between cognitive dysfunction and 5-serotonin receptor 3B subunit in patients with colon cancer after curative resection and its effect on prognosis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2019, 13(02): 162-165.
[5]	Cunhai Chen, Yanmei Song. Progress of clinical study on renal anemia treated with single dosage of recombinant human erythropoietin [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(01): 49-51.
[6]	Qianru Zhou, Jiali Ren, Yuanwei Wang, Ting Hu, Guangsheng Wang. Diagnostic value of morphological features detected by diffusion weighted imaging in anterior choroidal artery infarction [J]. Chinese Journal of Clinicians(Electronic Edition), 2019, 13(09): 669-674.
[7]	Jing Ding, Peiwen Li, Yingchun Xu. The application of Xingnao Kaiqiao acupuncture in severe neurological emergencies [J]. Chinese Journal of Acupuncture and Moxibustion(Electronic Edition), 2023, 12(04): 161-164.
[8]	Lina Ning, Jie Xiong. The therapeutic evaluation research on treating dysarthria after cerebral infarction with Xingnao Kaiqiao acupuncture and tongue acupuncture therapy [J]. Chinese Journal of Acupuncture and Moxibustion(Electronic Edition), 2023, 12(04): 146-150.
[9]	Changguang Song, Wenguo Liu, Aijun Mu. Application of detection of coagulation molecular markers in early diagnosis of cerebral infarction [J]. Chinese Journal of Diagnostics(Electronic Edition), 2018, 06(02): 124-128.
[10]	Junchen Zhang, Ran Zhang, Guangning Zhang, Wanju Zhao, Qingxia Kong, Yanli Hou. Effects of quercetin on the learning and memory ability of temporal lobe epilepsy in rats [J]. Chinese Journal of Diagnostics(Electronic Edition), 2016, 04(02): 131-135.
[11]	Zixuan Wang, Lan Tan, Jintai Yu. Clinical diagnosis thinking of dementia [J]. Chinese Journal of Diagnostics(Electronic Edition), 2015, 03(02): 109-113.
[12]	Zhanyong Sun, Liying Xun, Peiyuan Lyu. Application of computed tomography, magnetic resonance imaging, magnetoencephalography in the diagnosis of acute cerebral infarction [J]. Chinese Journal of Diagnostics(Electronic Edition), 2014, 02(01): 9-16.
[13]	Ying Pang, Mingting Liang, Jianqun Ma, Yong Yang, Jing Zhang. Protective effects and mechanisms of recombinant human erythropoietin on myocardial ischemia/reperfusion injury in rabbits [J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2017, 05(01): 1-6.
[14]	Jingyi Chen, Bin Liu, Weimin Ning, Jing Tan, Wenjun Zhou, Yu Peng. Clinical study of intravenous thrombolysis in acute cerebral infarction [J]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2016, 02(03): 161-165.
[15]	Gang Li, Min Li. Progress of regional cerebral oxygen saturation monitoring in the prevention of cerebral ischemia during cardiocerebrovascular surgery [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2020, 14(05): 264-267.

Please choose a citation manager

Content to export